GlassScriptPhysician profile
Payal Suthar
NPI 1679702781
$2,142.16
in general payments reported to CMS, 2019-2025
19 companies · $2,142 in 2025
The $2,142 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.16 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.06 | 2025 | |
| Janssen Biotech, INC. | $317.95 | 2025 | Tremfya |
| Amgen INC. | $316.11 | 2025 | Krystexxa, Otezla, Uplizna |
| Novartis Pharmaceuticals Corporation | $232.64 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $123.55 | 2025 | Saphnelo |
| Invivyd INC | $89.62 | 2025 | Pemgarda |
| E.R. Squibb & Sons, L.L.C. | $82.86 | 2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $77.09 | 2025 | Acthar |
| Radius Health, INC. | $52.79 | 2025 | Tymlos |
| Organon LLC | $41.94 | 2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $36.25 | 2025 | Benlysta |
| Madrigal Pharmaceuticals | $29.39 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $20.88 | 2025 | Strensiq |
| Ucb, INC. | $19.99 | 2025 | Bimzelx |
| Ascendis Pharma Endocrinology INC | $18.14 | 2025 | Yorvipath |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $16.02 | 2025 | Tonmya |
| Kyowa Kirin, INC. | $14.49 | 2025 | |
| Xeris Pharmaceuticals, INC. | $13.76 | 2025 | Gvoke Hypopen |
| Actelion Pharmaceuticals US, INC. | $9.63 | 2025 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payal Suthar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.